ROCHE HOLDING AG |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,383 MXN | +3.62% |
|
-2.27% | -11.18% |
| 05-31 | ROCHE HOLDINGS AG : Gets a Neutral rating from UBS | ZD |
| 05-31 | Transcript : Roche Holding AG - Shareholder/Analyst Call |
| Sales 2024 * | 60.36B 66.86B 1,137B 91.09B | Sales 2025 * | 63.82B 70.69B 1,203B 96.31B | Capitalization | 186B 207B 3,514B 281B |
|---|---|---|---|---|---|
| Net income 2024 * | 13.27B 14.7B 250B 20.03B | Net income 2025 * | 14.76B 16.35B 278B 22.28B | EV / Sales 2024 * | 3.32 x |
| Net Debt 2024 * | 13.79B 15.27B 260B 20.81B | Net Debt 2025 * | 7.91B 8.76B 149B 11.94B | EV / Sales 2025 * | 3.05 x |
| P/E ratio 2024 * |
13.6
x | P/E ratio 2025 * |
12.3
x | Employees | 103,605 |
| Yield 2024 * |
4.24% | Yield 2025 * |
4.36% | Free-Float | 88.91% |
More Fundamentals
* Assessed data
More news
Latest transcript on Roche Holding AG
More press releases
| 1 day | +3.62% | ||
| 1 week | -2.27% | ||
| 1 month | +9.58% | ||
| 3 months | -2.49% | ||
| 6 months | -7.04% | ||
| Current year | -11.18% |
1 week
4 230.16
4 383.24
1 month
4 182.634 484.92
Current year
4 000.085 020.22
1 year
4 000.085 516.46
3 years
4 000.088 541.36
5 years
4 000.088 906.23
10 years
3 712.118 906.23
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
| Director/Board Member | 59 | - | |
| Director/Board Member | 66 | 95-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 4,383 | +3.62% | 355 |
End-of-day quote Mexican S.E., May 30, 2024
More quotes
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
Pharmaceuticals
Calendar
2024-06-05
- Jefferies Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
231
CHF
Average target price
277.5
CHF
Spread / Average Target
+20.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +6.17% | 164B | |
| -0.45% | 162B | |
| -.--% | 122B |
- Stock Market
- Equities
- ROG Stock
- ROG N Stock
